Literature DB >> 8329009

Determination of ivermectin in human plasma by high-performance liquid chromatography.

D R Krishna1, U Klotz.   

Abstract

A specific reversed-phase HPLC-assay with sensitive fluorometric detection has been developed to measure the potent new antiparasitic agent ivermectin (CAS 70288-86-7) in human plasma (and urine). The lower limit of the method was 1 ng/ml and the intra-/interassay variability averaged 4.5/6.9%, respectively. The assay was applied for measuring plasma (urine) concentrations of ivermectin upto 56 (72 h) following a single oral dose of 6 and 12 mg. No unchanged or conjugated ivermectin could be detected in urine. Plasma concentrations increased linearly with dose but elimination half-life (12.6/13.4 h) was independent of the administered dose. Thus, the method is applicable for monitoring plasma levels during clinical and pharmacokinetic trials with ivermectin to evaluate its most efficacious dosage regimen.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329009

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

2.  Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.

Authors:  Urs Duthaler; Claudia Suenderhauf; Mats O Karlsson; Janine Hussner; Henriette Meyer Zu Schwabedissen; Stephan Krähenbühl; Felix Hammann
Journal:  Br J Clin Pharmacol       Date:  2019-01-24       Impact factor: 4.335

3.  The Effects of Ivermectin on Brugia malayi Females In Vitro: A Transcriptomic Approach.

Authors:  Cristina Ballesteros; Lucienne Tritten; Maeghan O'Neill; Erica Burkman; Weam I Zaky; Jianguo Xia; Andrew Moorhead; Steven A Williams; Timothy G Geary
Journal:  PLoS Negl Trop Dis       Date:  2016-08-16

4.  Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL).

Authors:  Menno R Smit; Eric O Ochomo; David Waterhouse; Titus K Kwambai; Bernard O Abong'o; Teun Bousema; Nabie M Bayoh; John E Gimnig; Aaron M Samuels; Meghna R Desai; Penelope A Phillips-Howard; Simon K Kariuki; Duolao Wang; Feiko O Ter Kuile; Stephen A Ward; Ghaith Aljayyoussi
Journal:  Clin Pharmacol Ther       Date:  2018-10-09       Impact factor: 6.875

5.  Electrochemical Detection of Ivermectin Used for the Treatment of COVID-19 with Glutardialdehyde-Modified Glassy Carbon Electrode.

Authors:  Berna Koçak; Yeliz İpek
Journal:  Electrocatalysis (N Y)       Date:  2022-01-05       Impact factor: 2.933

6.  Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.

Authors:  Jose Muñoz; Maria Rosa Ballester; Rosa Maria Antonijoan; Ignasi Gich; Montse Rodríguez; Enrico Colli; Silvia Gold; Alejandro J Krolewiecki
Journal:  PLoS Negl Trop Dis       Date:  2018-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.